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The First Case of Postpartum Acquired Hemophilia A in Korea
Acquired hemophilia A (AHA) is a rare coagulopathy caused by autoantibodies to 
coagulation factor VIII (FVIII). Most patients with AHA have been previously healthy; 
however, a variety of morbidities have been associated with the condition including 
pregnancy. A 40-yr-old woman visited our institution with extensive hematoma on the 
right hip area. Her medical history revealed no personal or familial history of bleeding 
diathesis. Her coagulation tests showed markedly prolonged aPTT (117 sec), markedly 
decreased level of FVIII activity (0.4%) and high-titer FVIII inhibitor (77 BU). Collectively, 
she was diagnosed as having postpartum AHA and was treated with bypassing agents and 
corticosteroids. Her aPTT was normalized on the 174th postpartum day and FVIII inhibitor 
showed negative conversion on the 224th postpartum day. This is the first case of 
postpartum AHA with high-titer FVIII inhibitor in Korea. Timely diagnosis and management 
can reduce morbidity and mortality of this potentially life-threatening condition.
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CASE REPORT
Laboratory Medicine
INTRODUCTION
Acquired hemophilia A (AHA) is a rare acquired coagulopathy 
caused by autoantibodies to coagulation factor VIII (FVIII) (1, 2). 
Although the estimated incidence of AHA is 0.2-1.0 case per one 
million population per year, cases with a low titer antibodies may 
be underestimated unless diagnostic coagulation tests are per-
formed in suspected individuals (3). Most of the affected patients 
have been previously healthy, with idiopathic AHA accounting 
for approximately 50% of cases (4). Immunologic disorders (such 
as systemic lupus erythematosus, rheumatoid arthritis, multi-
ple sclerosis and graft-versus-host disease after allogeneic bone 
marrow transplant), dermatological disorders, malignancy, old 
age and pregnancy have been known to be associated with the 
development of autoantibodies to factor VIII (1). Postpartum 
AHA constitutes 7% to 11% of patients with acquired FVIII in-
hibitors and is observed more often in primigravidas (1, 5) and 
has rarely been detected during pregnancy or labor (6). In most 
cases, the onset of symptoms is usually within a few days to 4 
months postpartum, but it may occur as late as 1 yr afterwards. 
Suspicion of the condition in unexplained postpartum bleed-
ing with prolonged aPTT and timely diagnosis and prompt man-
agement including bleeding control and eradication of the inhib-
itor by immunosuppressive therapy are important to improve 
the prognosis. 
  Here we report a case of AHA developed shortly after preg-
nancy and successfully treated with immunosuppressive treat-
ment and corticosteroids. To the best of our knowledge, this is 
the first report of postpartum AHA in Korea.
CASE DESCRIPTION
A 40-yr-old woman visited our hospital, on November, 9, 2009, 
with an extensive hematoma on right hip area. She had deliv-
ered a full-term baby from her second pregnancy uneventfully 
65 days before by Cesarean section at an outside institution. Five 
days after delivery, she presented with vaginal bleeding and high 
fever up to 40°C. She was transfused with packed red blood cells 
for anemia (Hb 6.0 g/dL) and received uterine arterial emboli-
zation therapy via femoral artery to control the vaginal bleeding. 
Swelling and pain on right femoral area where the arterial em-
bolization had been performed exacerbated and progressed to 
hematoma. Initial coagulation studies at our institution showed 
markedly prolonged aPTT (117 sec) (reference range, 29.1-41.9 
sec), which was not corrected on an immediate 1:1 mixing study 
with normal plasma (53.6 sec). The mixing test results by pro-
longed incubation for 1 and 2 hr at 37°C showed further prolon-
gation (73.7 and 96.7 sec, respectively), compatible with the pat-
tern of delayed-acting inhibitor. Factor assays revealed a mark-
edly decreased level of FVIII activity at 0.4% (severe), while other 
factor activities were within normal ranges. Anti-FVIII Ab assay 
revealed a high-titer FVIII inhibitor at 77 Bethesda units (BU). Lee JH, et al.  •  Postpartum Acquired Hemophilia A
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Tests for anti-phospholipid Ab revealed negative results for anti-
cardiolipin Abs and anti-beta 2 glycoprotein I Abs, while lupus 
anticoagulant (LA) tests were positive (PTT-LA 138.1 sec and 
Staclot LA 20.4 sec). Her medical history revealed that she did 
not have any significant medical history and familial history of 
coagulopathy. She had a history of induced abortion 2 yr previ-
ously, and the coagulation times on that occasion was reported 
to be within reference ranges (aPTT 26.1 sec and PT 0.91 INR). 
Collectively, she diagnosed with postpartum AHA with high-ti-
ter FVIII inhibitor. 
  Based on the diagnosis, she was treated with factor eight in-
hibitor bypassing activity (FEIBA, Baxter, Westlake Village, CA, 
USA), recombinant activated factor VII (NovoSeven, Novo Nor-
disk, Princeton, NJ, USA), and corticosteroids. She gradually re-
covered from hematoma with a progressive improvement of co-
agulation tests. Her aPTT was normalized (41.8 sec) on the 174th 
postpartum day, and FVIII inhibitor showed negative conversion 
on the 224th postpartum day (Fig. 1). Along with the normaliza-
tion of aPTT, tests for LA also demonstrated negative results. She 
is currently on routine follow-up without any oral prednisone 
or hemorrhagic manifestations. 
DISCUSSION
AHA is a condition of potentially life-threatening bleeding dia-
thesis caused by autoantibodies against FVIII. While FVIII allo-
antibodies can occur in 20%-30% of patients with severe form 
of hereditary hemophilia, FVIII autoantibodies can be acquired 
spontaneously in postpartum women, in patients with immu-
nologic disorders or with other conditions such as malignancy 
who previously had normal levels of FVIII, or in old age (7). The 
patient described in the present report was relatively young and 
did not have a past medical history relevant to the development 
of AHA. Taking the clinical course of the occurrence of inhibitor 
following pregnancy, the diagnosis of post-partum AHA was clin-
ically established. The presence of non-specific inhibitor was 
not likely based on the findings of negative solid-phased Abs 
(anti-cardiolipin and anti-beta2 glycoprotein I). The screening 
and confirm tests for LA were initially positive; however, posi-
tive LA tests by the Staclot LA reagent along with negative solid-
phase tests could be considered to be due to the interference of 
anti-FVIII Ab with phospholipid-dependent coagulation test 
rather than true presence of LA (8). Indeed, the LA tests revealed 
negative values along with the normalization of aPTT after treat-
ment. Unfortunately, extensive laboratory workup to search for 
other underlying conditions was not performed due to the emer-
gent situation of the patient. Risk factors and pathogenesis of 
pregnancy-related FVIII autoantibodies still remain unclear (9). 
As these inhibitors develop more frequently during the postpar-
tum period, it was hypothesized that the mother developed an-
tibodies when exposed to fetal FVIII during the delivery (10). 
However, this theory does not explain the absence of an anam-
nestic response in subsequent pregnancies. A review of the lit-
erature revealed that there were no recurrences on second preg-
nancies in 8 patients with postpartum FVIII inhibitors whose 
inhibitors had disappeared (11). In our case, the patient present-
ed the initial symptom 5 days after her second delivery. How-
ever, the appropriate management was not instituted until post-
partum day 77 due to delayed diagnosis. Patients with acquired 
inhibitors typically do not have a personal or family history of 
bleeding episodes, which could lead to increased morbidity and 
mortality from uncontrolled hemorrhage because of the delay 
of diagnosis. In addition, pregnancy itself is a blood-losing event 
and could be accompanied by changes in the coagulation sys-
tem (6). Although postpartum AHA is known to have a favorable 
outcome with a high percentage of spontaneous remissions, the 
mortality due to hemorrhage has been reported between 12% 
and 22% (2, 3, 12). In particular, the prognosis is worse in patients 
with a high-inhibitor titer, low FVIII plasma activity, and high 
transfusional requirements. Therefore, recognition of this con-
dition, clinical suspicion, and timely diagnosis by appropriate 
coagulation workup are important to reduce morbidity and mor-
Fig. 1. Clinical course of the present case of postpartum 
acquired hemophilia A.  Days from C-sec delivery
52.3
95.2
140.7
116.9
65.7
107.7
73.7
48.7
41.8
38.6 41.6
10.4
0.4 1.3
20
57
2.2
52
77
12.8
0.54 Negative
  0  5  65  68  77  90  107  128  153  174  198  224
160
140
120
100
80
60
40
20
0
aPTT (sec)
FVIII inhibitor (BU/mL)
FVIII: C (%)Lee JH, et al.  •  Postpartum Acquired Hemophilia A
http://jkms.org   1249 http://dx.doi.org/10.3346/jkms.2011.26.9.1247
tality of postpartum AHA. In our case, the patient had high-titer 
FVIII inhibitor (76.8 BU), which persisted until postpartum day 
224 despite the treatment with bypassing agent and corticoste-
roids. This is in line with the previous observation that high-titer 
inhibitors (> 10 BU) do not easily disappear spontaneously and 
may be resistant to treatment with immunosuppressive thera-
py. On the other hand, if the inhibitor titer is low (< 5 BU), the 
inhibitors generally disappear spontaneously and do not recur 
on subsequent pregnancies (13). 
  The first aim of the management of postpartum AHA is to con-
trol acute bleeding, while the final aim is to accelerate eradica-
tion of the inhibitors (14). Bypassing agents are currently the 
most widely used first-line treatment, and both rFVIIa and FEI-
BA have been shown to be effective for bleeding control. When 
a large amount of activated factor VII is infused, tissue factor is 
not required and the factor VIIa directly activates factor X on the 
surface of activated platelets, bypassing FVIII and FIX and thus 
circumventing the actions of inhibitory antibodies developed 
(15). For the eradication of FVIII inhibitor, immunosuppressive 
therapy with corticosteroids and cytotoxic drugs, alone or in com-
bination, has been the mainstay of therapy for the enduring re-
mission. Also, it has been recently reported that rituximab (anti-
CD20 monoclonal antibody) and the extracorporeal removal of 
the autoantibody by plasmapheresis were effective especially 
in cases with very high-titer inhibitors (16-18).
  There have been a couple of published reports on AHA in 
Korea, in associated with Mycoplasma pneumoniae infection 
and Cobra toxin intake (19, 20). However, this is the first report 
on postpartum AHA in Korea. Suspicion of postpartum AHA and 
timely diagnosis and management are critical to reduce morbid-
ity and mortality in this rare but potentially life-threatening con-
dition. 
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